Literature DB >> 29112087

Fecal Amino Acid Analysis Can Discriminate De Novo Treatment-Naïve Pediatric Inflammatory Bowel Disease From Controls.

Sofie Bosch1, Eduard A Struys2, Nora van Gaal1, Abdellatif Bakkali2, Erwin W Jansen2, Kay Diederen3, Marc A Benninga3, Chris J Mulder1, Nanne K H de Boer1, Tim G J de Meij4.   

Abstract

OBJECTIVES: Endoscopy remains mandatory in the diagnostic work-up of inflammatory bowel disease (IBD), but is a costly and invasive procedure. Identification of novel, noninvasive, diagnostic biomarkers remains a priority. The aim of the present study was to explore the potential of fecal amino acid composition as diagnostic biomarker for pediatric IBD.
METHODS: In this case-control study, treatment-naïve, de novo pediatric patients with IBD from two tertiary centers were included. Endoscopic severity of ulcerative colitis (UC) and Crohn's disease (CD) was based on physician global assessment scores, substantiated by levels of fecal calprotectin and C-reactive protein at study inclusion. Patients were instructed to collect a fecal sample prior to bowel cleansing. Healthy controls (HCs) were recruited from primary schools in the same region. Dedicated amino acid analysis was performed on all samples.
RESULTS: Significant differences between 30 IBD patients (15 UC, 15 CD) and 15 age and sex-matched HCs were found in six amino acids (histidine, tryptophan, phenylalanine, leucine, tyrosine, and valine; all area under the curve >0.75 and P < 0.005), displaying higher levels in IBD. When distributing the patients according to type of IBD, a similar spectrum of amino acids differed between UC and HC (histidine, tryptophan, phenylalanine, leucine, valine, and serine), whereas three amino acids were different between CD and HC (histidine, tryptophan, and phenylalanine).
CONCLUSIONS: Significantly increased levels of six different fecal amino acids were found in patients with IBD compared to controls. Whether these differences reflect decreased absorption or increased loss by inflamed intestines needs to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29112087     DOI: 10.1097/MPG.0000000000001812

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  9 in total

1.  Fecal amine metabolite analysis before onset of severe necrotizing enterocolitis in preterm infants: a prospective case-control study.

Authors:  N Deianova; S El Manouni El Hassani; E A Struijs; E E W Jansen; A Bakkali; M A van de Wiel; W P de Boode; C V Hulzebos; A H van Kaam; B W Kramer; E d'Haens; D C Vijlbrief; M M van Weissenbruch; W J de Jonge; M A Benninga; H J Niemarkt; N K H de Boer; T G J de Meij
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

Review 2.  Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites.

Authors:  Andrea Verdugo-Meza; Jiayu Ye; Hansika Dadlani; Sanjoy Ghosh; Deanna L Gibson
Journal:  Nutrients       Date:  2020-05-15       Impact factor: 5.717

Review 3.  The Role of Dietary Nutrients in Inflammatory Bowel Disease.

Authors:  Kohei Sugihara; Tina L Morhardt; Nobuhiko Kamada
Journal:  Front Immunol       Date:  2019-01-15       Impact factor: 7.561

4.  The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma.

Authors:  Sofie Bosch; Animesh Acharjee; Mohammed N Quraishi; Patricia Rojas; Abdellatif Bakkali; Erwin Ew Jansen; Marina Brizzio Brentar; Johan Kuijvenhoven; Pieter Stokkers; Eduard Struys; Andrew D Beggs; Georgios V Gkoutos; Tim Gj de Meij; Nanne Kh de Boer
Journal:  Gut Microbes       Date:  2022 Jan-Dec

5.  Fecal Amino Acid Analysis in Newly Diagnosed Pediatric Inflammatory Bowel Disease: A Multicenter Case-Control Study.

Authors:  Jasmijn Z Jagt; Eduard A Struys; Ibrahim Ayada; Abdellatif Bakkali; Erwin E W Jansen; Jürgen Claesen; Johan E van Limbergen; Marc A Benninga; Nanne K H de Boer; Tim G J de Meij
Journal:  Inflamm Bowel Dis       Date:  2022-05-04       Impact factor: 7.290

Review 6.  Inflammatory Bowel Disease and COVID-19: How Microbiomics and Metabolomics Depict Two Sides of the Same Coin.

Authors:  Gian Mario Cortes; Maria Antonietta Marcialis; Flaminia Bardanzellu; Angelica Corrias; Vassilios Fanos; Michele Mussap
Journal:  Front Microbiol       Date:  2022-03-21       Impact factor: 6.064

7.  Simultaneous Assessment of Urinary and Fecal Volatile Organic Compound Analysis in De Novo Pediatric IBD.

Authors:  Sofia El Manouni El Hassani; Sofie Bosch; Jesse P M Lemmen; Marina Brizzio Brentar; Ibrahim Ayada; Alfian N Wicaksono; James A Covington; Marc A Benninga; Nanne K H de Boer; Tim G J de Meij
Journal:  Sensors (Basel)       Date:  2019-10-16       Impact factor: 3.576

8.  Lactobacillus reuteri Ameliorates Intestinal Inflammation and Modulates Gut Microbiota and Metabolic Disorders in Dextran Sulfate Sodium-Induced Colitis in Mice.

Authors:  Gang Wang; Shuo Huang; Shuang Cai; Haitao Yu; Yuming Wang; Xiangfang Zeng; Shiyan Qiao
Journal:  Nutrients       Date:  2020-07-31       Impact factor: 5.717

9.  Metabolic Fluctuations in the Human Stool Obtained from Blastocystis Carriers and Non-Carriers.

Authors:  Emma L Betts; Jamie M Newton; Gary S Thompson; Fakhriddin Sarzhanov; Vasana Jinatham; Moon-Ju Kim; Siam Popluechai; Funda Dogruman-Al; Eun-Jeong Won; Eleni Gentekaki; Anastasios D Tsaousis
Journal:  Metabolites       Date:  2021-12-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.